During this webinar, Leonard van den Berg, MD, PhD (Chairman TRICALS | UMC Utrecht, NL) and Ruben van Eijk MD, PhD (Lead Statistician TRICALS | UMC Utrecht, NL) will discuss Primary endpoints in ALS clinical trials, differences in regulatory requirement of the EMA and FDA and statistical considerations.

They touched upon:

  • Primary endpoints in ALS clinical trials
  • Regulatory requirements: differences between EMA and FDA
  • Statistical considerations for ALSFRS-R, survival and composites

Followed by a Q&A session.

Speakers: Prof. Leonard van den Berg, MD, PhD & Dr. Ruben van Eijk, MD, PhD